Braftovi 75 mg hard capsules, Erbitux 5 mg/mL solution for infusion
FFCD 2006 NEORAF
Phase 2 small_molecule active
Quick answer
Braftovi 75 mg hard capsules, Erbitux 5 mg/mL solution for infusion for BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER is a Phase 2 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CERO THERAPEUTICS HOLDINGS, INC.
- Indication
- BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active